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Background: Gait deficits are important clinical symptoms of Parkinson’s disease (PD). However, existing behavioral
tests for the detection of motor impairments in rodents with systemic dopamine depletion only measure akinesia
and dyskinesia, and data focusing on gait are scarce. We evaluated gait changes in the methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced C57BL/6 murine model of PD by using a computer-assisted CatWalk system.
Correlations of gait parameters with tyrosine hydroxylase (TH) protein levels in the substantia nigra (SN) were also
investigated.
Results: The gait readouts, including the walking duration, variation of walking speed, step cycle, duty cycle, stance,
initial dual stance, terminal dual stance, three- and four-point supports, and the base of support between hind
limbs was noted to increase significantly one week after MPTP injection. In contrast, values of the stride length,
cadence, swing speed, and diagonal dual support decreased substantially following MPTP treatment (p < 0.05). All
of these changes lasted for three weeks after the last MPTP administration. Except for the stance in the fore limbs
and the swing speed in the hind limbs, the gait variability in the PD mice showed a closer correlation with the
protein levels of TH in the SN than the walking distances in the conventional open field test. Coordination
parameters of the regularity index and step pattern were not affected in mice treated with MPTP.
Conclusion: Data of the study suggest that the computer-assisted CatWalk system can provide reliable and objective
criteria to stratify gait changes arising from MPTP-induced bilateral lesions in C57/BL6 mice. The extent of gait changes
was noted to correlate with the expression of the biomarker for dopaminergic neurons. This novel analytical method may
hold promise in the study of disease progression and new drug screening in a murine PD model.
Keywords: Parkinson’s disease, Gait, MPTP, Tyrosine hydroxylase, Neurochemical correlationBackground
Parkinson’s disease (PD) is a pervasive motor disorder
resulting from the depletion of dopamine (DA) in the
nigrostriatal region of the central nervous system [1].
Gait variability and postural instability are prominent as
PD progresses [2]. Rhythmical walking of PD patients is
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reproduction in any medium, provided the orwhich are related to reduction in the dopamine level
[3,4]. The postural instability in PD patients often results
in falls, when turning around or stepping up, leading to
various injuries [5]. The motor deficits are the direct
consequence of DA loss in the nigrostriatal system [1].
Tyrosine hydroxylase (TH) is the key enzyme in DA syn-
thesis, as it converts tyrosine into levodopa, and is often
used as a biomarker for dopaminergic neurons [6,7].
Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a
neurotoxin being systemically administered to animals for
experimental studies of PD [8,9]. It can induce neuro-
pathological changes that mimic those of idiopathic PD in
experimental animals, especially in C57/BL6 mice [10,11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MPTP-induced animal models include the open field test
[12,13], rotarod test [14,15], swimming test [16], and nest
building test [17], which results may vary [18-20]. Experi-
mental factors such as timing of testing (day or night),
training intention, and testing environment, influence the
readouts. Observable changes may be weak and the indica-
tors of these tests, which are usually applied to unilaterally
lesioned animals, may not be sufficiently sensitive to dem-
onstrate the functional deficits in bilaterally injured animal
models. Besides, animals are tested in an involuntary state
and the test indicators, which are limited to either static or
dynamic state, cannot adequately display both readouts
simultaneously.
Gait analysis has already been described and applied to
the assessment of movement disorders in PD [21-24].
Much effort has been made to analyze the gait in animal
PD models, nevertheless there is a surprising lack of valid-
ation and characterization of gait variability in bilaterally
lesioned animal models [23,25-32]. Alexander et al. investi-
gated gait patterns and co-ordinations between limbs of
rats subjected to unilateral 6-hydroxydopamine (6-OHDA)
lesion by using footprint analysis and ladder walking test
[26]. Chuang et al. evaluated gait patterns in a unilaterally
6-OHDA-induced rat model [33]. Fernagut et al. first
introduced the manual measurement of stride length
using foot prints in bilaterally MPTP-induced lesioned
C57/BL6 mice [25]. Goldberg and co-workers assessed
stride length, stride frequency, stride duration, variability
in stride length, and paw area in MPTP-treated mice
having been stressfully trained on treadmill apparatus [23].
Westin et al. investigated gait disorders in 6-OHDA-
treated rats by a less commonly used bilateral induction
method [34].
In this report we described a novel procedure to validate
gait variability in a mouse model of sub-acute PD of
bilateral lesion induced by MPTP. We evaluated the
temporal expressions of TH protein in the SN and striatum
of MPTP-treated mice and assessed the neuro-degeneration
in the nigrostriatal regions by studying the correlation of
TH expressions with changes of gait parameters.
Methods
Animals
Inbred strain of adult male mice C57BL/6 at aged
8–10 weeks and weighting 25–28 g were used in the
study. They were kept in micro-isolator cages with
access food and water ad libium in a temperature-
controlled environment at 21°C and 12-hour cycle of
light and dark. Animals were amenable daily to the
researchers for one week prior to any experiment.
Experimental procedures were performed according
to the guidelines of the Animal Experiment Ethics
Committee of the Chinese University of Hong Kong.Experiment design
The design of the study is shown in Figure 1. C57BL/6
mice were allowed to familiarize with the CatWalk
device daily and cross the runway in a consistent
manner for one week before any experimentation. The
mice were then randomly divided into two groups.
MPTP-HCl (Sigma, St Louis, MO, USA) at 30 mg per
kg body weight per day was injected intra-peritoneally
into 50 mice for five consecutive days to induce PD.
Normal saline in equal volume of MPTP-HCl was
injected into 45 control mice. Upon completion of the
administration of either MPTP or normal saline, mice
were subjected to computer-assisted CatWalk tests on
day 7 and day 21 and open field tests on days 4, 7,
12, 16, and 21.
Western blotting was performed to analyze TH expres-
sions in the SN and striatum of mice two days before and
on days 2, 4, 7, 12, 16, and 21 after the course of MPTP
administration. Immuno-histochemical staining of TH was
conducted to assess the loss of dopaminergic neurons in
the SN and striatum of the mice three weeks post-injection
of MPTP.
Gait analysis
Gait of unforced moving mice was analyzed with the Cat-
Walk XT (Noldus Information Technology, Wageningen,
Netherlands). Details have been described previously [35].
CatWalk XT consists of a hardware system of a long, glass
walkway plate, illuminated with green light, a high-speed
video camera, and a software package for quantitative
assessment of animal footprints. Green light is reflected
within the glass except at points being touched. It scatters
and illuminates the contact area. The intensity of the area
of illumination, which is proportional to the exerted
pressure, is digitally captured by the video camera and
analyzed.
Mice were allowed to walk across the glass walkway
in an unforced manner at least six times a day on day 7
prior to injection with either MPTP or normal saline.
Mouse tracks that were straight without any interruption
or hesitation were treated as successful runs. Runs with
any wall climbing, grooming, and staying on the walkway
were not analyzed. Mice that failed the CatWalk training
were excluded from the study. An average number of 8
replicate crossings (range: 4–6) made by each mouse was
recorded. The CatWalk software was used to analyze
crossings that had at least five cycles of complete steps.
Table 1 shows the definition of the gait and co-ordination
parameters used in this study.
Open field test
Spontaneous locomotor activity in mice was measured
using the open field test. Mice were allowed to adapt to
the environment for two hours prior to testing. They
CatWalk test
Open field test 





Western Blotting                
Figure 1 Flow chart of the study.
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white square box measuring 50 × 50 × 25 cm and kept
for 10 minutes under normal lighting. Movements and
trajectories of mice were video-taped and analyzed by
the Videomex-One software (Columbus Instruments,
USA). The box was cleaned with water and 70% alcohol
after each testing to remove the body scent, which
could be a cue to move for mice in subsequent evalua-
tions. Eight mice per study arm and time point were
recruited.Table 1 Definitions of gait parameters
Parameter Definition
Run duration Time of finishing an e
Maximum area The print area of paw
Maximum intensity Maximum pressure of
Stride length The distance between
Swing duration The duration in secon
Swing speed The ratio of stride leng
Stance The time duration in s
Step cycle The time in seconds b
Duty cycle The percentage of sta
Cadence Steps per second in a
Base of support Distance between fore
Initial dual support The first time in a step
with the glass plate




Four-point Support The relative duration o
Step Pattern Configuration of right
Alternate Aa: RF-RH-LF-LH; Ab: LF-RH-RF-LH
Cruciate Ca: RF-LF-RH-LH; Cb: LF-RF-LH-RH
Rotary Ra: RF-LF-LH-RH; Rb: LF-RF-RH-LH
Regularity Index The number of normaTissue processing
Before and upon completion of MPTP injection on day −2
and days 2, 4, 7, 12, 16, and 21, respectively, four mice were
anesthetized, their thoraxes were cut open, and they were
trans-cardiacally perfused with physiologic saline and 4%
paraformaldehyde in 0.1 M of phosphate-buffered saline.
Heads were decapitated. Brains were rapidly removed and
fixed in 4% paraformaldehyde for two days at 4°C, and
allowed to further fix in 15%, 20%, and 30% sucrose
solution.ntire run in second
when the braking phase turns into propulsion phase
paw contacting floor
two consecutive travels in the same paw
ds of no contact of a paw with the glass plate
th to swing duration
econds of paws in contact with glass plate
etween two consecutive initial contacts of the same paw
nce over the sum of stance and swing duration
trial
limbs or hind limbs at maximum area
cycle of a hind paw that the contralateral paw also makes contact
step cycle of a paw that the contralateral paw also makes contact with
f simultaneous contacts of limbs with the glass plate
(R), left (L), front (F) and hind (H) limbs
l step sequence patterns relative to the total number of paw placements
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was adopted to maximize the isolation of ventral midbrain
containing the substantia nigra [36]. The brain was quickly
removed and put into a chilled mouse coronal brain matrix
(World Precision Instruments Inc., USA). A 2-mm-thick
posterior-anterior segment was dissected from the posterior
aspect of the cerebral peduncles. The caudal aspect of the
dissected section was immediately placed on the disk with
the ventral aspect facing the researcher. After the middle
brain was separated, the substantia nigra-rich tissue was
isolated by cutting at a third of the way from the dorsal
midbrain with a blade slanted at a 45° angle toward the
researcher. The striatum was dissected from the brain
immediately. All of the brain tissues were stored at −80°C
until analysis.
Western blot analysis
Brain tissues was homogenized in ice-cold lysis buffer
containing 50 mM Tris–HCl at pH 6.8, 50 mM NaCl,
1% Triton X-100, 1 mM PMSF, 5 μg/ml of aprotinin,
1 μg/ml of leupeptin and 1 μg/ml of prepstetin (ICN Bio
Medical Products, Costa Mesa, CA). The lysates were
centrifuged at 12,000 x g for 30 minutes at 4°C to separ-
ate debris. The protein concentration was assayed using a
BIO-RAD DC protein assay kit (BioRad, Hercules, CA).
Ten μg of protein was used for the western blot analysis.
Protein samples were electrophoresed on 10% SDS-
PAGE and blotted onto nitrocellulose membranes (BioRad,
Hercules, CA). Having blocked for an hour at room
temperature with 20 mM Tris–HCl at pH 7.5, 137 mM
NaCl, 0.05% Tween 20 and 5% non-fat milk (BioRad,
Hercules, CA). proteins on membranes were incubated
with polyclonal rabbit anti-TH (1:3,000, clone AB152,
Chemicon International, USA), polyclonal goat anti-β-
actin (1:1,000, Santa Cruz, USA) overnight at 4°C.
Membranes were washed three times and then stained
with fluorescein isothiocyanate-conjugated secondary
antibody (1:20,000, Rockland, USA) for an hour at room
temperature. Upon completion of washings, green fluores-
cent signals were visualized using the OdysseyW imaging
system (LICOR Biosciences, version 3.0). The optical density
was read using the Odyssey system.
Immunohistochemical staining of TH
Cryostat sections of brain slices in cryo-mountant were
cut 25 μm thick. Floating sections on 0.01 M phosphate
buffered saline were exposed to 0.25% Triton X-100 and
3% H2O2, and then blocked in 2% bovine serum albumin.
They were then incubated sequentially with rabbit
polyclonal anti-TH antibody (1: 1,000, clone AB152,
Chemicon International, USA), biotinylated goat anti-
rabbit antibody (1:200, Vector Laboratories, USA) and
horseradish-peroxidase-conjugated avidin-biotin complex
(Vector Laboratories, USA). Sections were developed witha DAB kit (Zymed Laboratories Inc, USA). Dark brown
signals derived from sections mounted on glass slides were
captured and analyzed using a microscope Axioplan 2
(Zeiss, Germany) equipped with a documentation system.
Unbiased stereological counting method was used to
enumerate the DA neurons [37]. Every sixth section of
the SN was analyzed by means of the optical fractionator
and a computer-assisted stereological Olympus Toolbox
system version 2.1.4. The SN of each hemisphere was
first delineated using a 4x objective. A square grid of
150 × 150 μm was randomly super-imposed with and a
100 × 100 μm square dissector counting chamber placed
on the first counting area of the image and then system-
ically moved through all of the counting areas until the
entire delineated section was counted. The striatum
of each section was located under the same identical
condition. Analyses of the TH-immunoreactive profiles
were restricted to the SNpc and thus excluded the
ventral tegmental area. The optical density of the TH-
immuno-reactive fibers was evaluated by the software
Metamorph 6.3 on 9–11 sections spanning the striatum.
The background signal captured from the corpus callosum
was subtracted from the readout of the optical density of
each striatal section. Scorings of TH-immuno-reactivity
and optical density were performed by two researchers in
a blind manner. Results derived from 9–11 sections were
averaged.
Statistical analysis
All the data were expressed as mean ± standard error of
mean (SEM). One-way ANOVA was used for the statistical
evaluation of gait changes in the CatWalk test. Repeated-
measure one-way ANOVA was used to statistically analyze
the path lengths in the open field test at various time inter-
vals after MPTP injection. The correlations of the TH
protein levels in the SN with the motor parameters in the
CatWalk test and open field test were evaluated by the
Pearson’s product–moment correlation coefficient. Differ-
ences in the expression levels of TH protein at different
time points were analyzed by ANOVA and the Student–
Newman–Keuls post hoc test. Quantitative differences of
TH-immuno-reactive cells in SN were evaluated using the
Student’s t-test. A p value ≤ 0.05 was considered as statisti-
cally significant. All of the data were analyzed using the
SPSS 17.0 software (SPSS Inc., Chicago, USA).
Results
Catwalk test
Gait of mice was evaluated with CatWalk system at one
week and three weeks upon completion of the adminis-
tration of either MPTP or normal saline. A decrease in
the stride length and an increase in variation of stance
and swing were noted in the MPTP-treated mouse com-
pared to the control mouse. Besides, A fall in diagonal
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supports were evident (Figure 2). Abnormal gait persisted
over the three-week study period. A mean ± SEM of
walking duration taken by eight mice on day 21 post-
MPTP treatment was significantly longer than that of
eight control mice having normal saline injection (time in
seconds: MPTP-induced PD mice vs. control mice; 3.099 ±
0.689 seconds vs. 1.708 ± 0.308 seconds; p ≤ 0.01,
Figure 3A). The extent of variation in walking speed of
MPTP-treated mice was more profound than that of the
control mice (MPTP-induced PD mice vs. control mice;
34.92 ± 3.61% vs. 24.44 ± 2.49%, p = 0.019, Figure 3B). The
cadence of MPTP-treated mice dropped significantly (steps
per second: MPTP-induced PD mice vs. control mice;
15.18 ± 0.52 vs. 19.19 ± 0.68; p ≤ 0.05, Figure 3C).
The swing speeds of paws deteriorated markedly
(Figure 3D) and the stride lengths of limbs decreased
significantly (Figure 3E), whereas the stances, duty cycles,
and step cycles of paws increased substantially (Figures 3
F–H). The initial dual stance and terminal dual stance of
paw were also prolonged in MPTP-treated mice com-
pared with those of control counterparts (Figure 4A–B).
A relative decrease in diagonal dual support was noted in
MPTP-treated mice (incidence of diagonal dual support:
MPTP-induced PD mice vs. control mice; 59.76 ± 3.06%
vs. 80.52 ± 1.77%, p ≤ 0.0001, Figure 4C). Significant
increases of three-point support and four-point support
were noted in MPTP-treated mice (incidence of three-
point support: PD mice vs. control mice; 25.99 ± 3.26%
vs. 8.07 ± 1.62%; p ≤ 0.0001; Figure 4D, incidence of










Figure 2 Representative illuminations of footprints.vs. 1.24 ± 0.47%; p ≤ 0.0001; Figure 4E). The bases of
support between hind limbs were relatively longer
(PD mice vs. control mice; 4.12 ± 0.08 cm vs. 3.63 ±
0.06 cm; p ≤ 0.0001; Figure 4F).
On the other hand, readouts of gait parameters of
maximum pressure intensity, maximum contact area,
and swing duration of paws of MPTP-treated mice and
control mice are comparable (data are not shown).
There was also no significant difference in inter-limb
coordination among PD mice and normal mice.
Step patterns and regularity index are indices of
coordination, and in these two measures there were no
differences between the treated group and the controls.
It may be that the motor dysfunction induced by the
nigrostriatal lesion in this study did not affect the coord-
ination of the tetrapods. This supposition is supported
by the results of Chuang and his colleague [33].
Open field test
The locomotor activity was measured by means of the
open field test to investigate the time course of changes
in spontaneous activity induced by the MPTP. Repeated-
measure one way ANOVA revealed the effect of the
number of times of repetitive tests (F4,11 = 106.6;
p < 0.001) and the treatment interaction (F4,11 = 42.865;
P < 0.001), indicating that MPTP treatment affected
spontaneous activity compared with saline treated mice
(Figure 5). The distances travelled by mice on day 4
and at three weeks after the last injection of MPTP
were significantly less than those of the vehicle-treated

















































































































































Figure 3 Gait variability three weeks post-MPTP administration.
Wang et al. BMC Neuroscience 2012, 13:142 Page 6 of 13
http://www.biomedcentral.com/1471-2202/13/142




























































































































Figure 4 Gait changes three weeks post-MPTP administration.
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http://www.biomedcentral.com/1471-2202/13/142Expression and correlation of TH with gait variability
A significant fall in TH was evident in both substantia
nigra and striatum of mice starting on day 2 of MPTP
administration, followed by a slight rebound at two
weeks. TH then remained at the lowest levels on three
weeks post-MPTP injection. It was noted that the down-
regulation of TH by MPTP in the striatum was more
profound than that in the substantia nigra (Figure 6).
Table 2 shows the significantly positive correlations of
the levels of TH in the substantia nigra of MPTP-treated
mice with readouts derived from CatWalk tests of diagonal
dual support, stride length in all limbs, and swing speed in
the forelimbs three weeks post MPTP administration.
Substantially negative correlations of TH levels with stance
in the hind limbs, step cycle, duty cycle, initial dual stance,
terminal dual stance, three-point support, four-point sup-
port, walking speed variation, cadence,and base of support
between hind limbs were noted. On the other hand, the
levels of TH correlated poorly with the trajectories in the
open field tests.Histological markers of nigrostriatal degeneration
induced by MPTP
Immuno-histochemical staining of TH demonstrated a
substantial loss of immuno-reactivity in the SN and
striatum of mice three weeks post-MPTP administration
(Figure 7). Unbiased stereological counting displayed a
significant loss of up to 57.04% compared with the
control group on the 21st day after the last injection of
MPTP (p < 0.05). Injection with MPTP also resulted in a
great depletion of TH-ir in the striatum of up to 61.32% of
that in control group on the 21st day post-treatment. Data
suggest that deprivation and denervation of TH-immuno-
reactive neurons and terminals might be attributed to the
gait variability experienced by MPTP-treated mice.
Discussion
Quantitative assessment of gait
In this study, we developed a time-efficient and animal-
friendly CatWalk test of motor functions in an MPTP-
induced PD mouse model. Both static and dynamic
AB
Figure 6 Western immunoblotting of tyrosine hydroxylase (TH) in the substantia nigra and striatum of mice before, on and post MPTP
administration.
Figure 5 Representative trajectories and locomotor activity in open field test.
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LF -0.183 0.235 LF -0.444 0.003
LH -0.420 0.003 LH -0.594 0.0001
RF -0.191 0.215 RF -0.422 0.004
RH -0.447 0.002 RH -0.717 0.0001
Stride length Initial dual support
LF 0.759 0.0001 LF -0.385 0.01
LH 0.725 0.0001 LH -0.466 0.001
RF 0.660 0.0001 RF -0.354 0.019
RH 0.568 0.0001 RH -0.419 0.001
Swing speed Terminal dual support
LF 0.393 0.008 LF -0.455 0.002
LH 0.252 0.099 LH -0.385 0.010
RF 0.359 0.007 RF -0.497 0.001
RH 0.288 0.058 RH -0.357 0.022
Step cycle Diagonal dual support 0.677 0.0001
LF -0.463 0.001 Three-point support -0.589 0.0001
LH -0.301 0.046 Four-point support -0.455 0.002
RF -0.453 0.002 Speed variation -0.469 0.001
RH -0.368 0.014 Cadence -0.346 0.021
Distance in open field test 0.206 0.358 Base of support between hind limbs -0.569 0.001
LF: left front, LH: left hind, RF: right front, RH: right hind.
A B C D
Figure 7 Enumeration of neurons expressing tyrosine hydroxylase (TH) in the substantia nigra and striatum of mice three weeks post-MPTP
administration.
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http://www.biomedcentral.com/1471-2202/13/142parameters of gait variability were collected simultaneously.
Static parameters of stance, print length, print width, print
area, maximum contact intensity, and maximum contact
area are based upon contacts of individual paw with the
glass plate of walkway. Dynamic parameters are walk
duration, variation of walk speed, swing speed, and base of
support between limbs. The study showed that the
CatWalk test was able to sensitively assess gait disorder
and inter-limb coordination deficit in a mouse model of
PD with bilateral lesion of DA neurons.
There are many behavioral tests in MPTP-induced PD
mouse model. These have to be robust and sensitive, in
order to detect functional changes, days and even weeks
after challenge by a neuro-toxin. The widely employed
rotarod test is a feasible means to analyze coordination
disorders in a bilaterally lesioned PD mouse model, but
it is insensitive. It was noted that the progress of pre-
analytical training of animals may recruit DA in the
striatum [38]. The pole-, grid- and nest-building tests
are sensitive to striatal DA level in MPTP-treated mice,
but are heavily dependent on the skilled manipulation of
fore-limbs of the animal being studied [17,39,40].
The open field test is the most commonly used
method to evaluate motor deficits because of its ease
and rapidity of use and rapidity in animals following
MPTP insult [12,41-45]. We conducted open field test to
study motor deficits in mice three weeks after induction of
sub-acute neural injury and applied the open field test as
the control in the evaluation of the CatWalk test. Readouts
of the open field test in the study agree with previous
reports of significant motor deficits in mice a few days after
MPTP injection [43,44]. A significant upsurge of trajec-
tories was also noted in mice one week post-MPTP
administration compared to those read on day 4 and
that of control mice on day 7. The scenario might be
attributable to an increase of DA metabolism and fluctu-
ation of catecholamines such as 5-hydroxytryptamine in
the midbrains of mice induced by dopaminergic neurotic
and MPTP and a booster of muscle strength to balance
posture instability [46-49].
Although open field test is a friendly test, the time
points to detect locomotor changes in animals are limited.
Here, we could only apply the time points of the 4 day
and three weeks after MPTP injury for the functional
evaluation in the open field test. The stability of behavioral
performance of animals in the open field is vulnerable
to the toxic effects of MPTP on biogenic amines inside
and outside the brain [44], administration regimens and
dosages of MPTP [48,50] and environments.
The computer-assisted CatWalk test paralleled the
motor function assessment in the open field test by
collecting static and dynamic parameters in non-stressed
rodents to investigate gait variability and coordination
changes simultaneously. The stride length, run duration,stance, step cycle, duty cycle, swing speed, and cadence
can be used to assess gait changes. The base of support
between limbs, initial dual stance, terminal dual stance
and diagonal dual support, three-point support and
four-point support reflects the posture alterations. The
regularity index and step sequence evaluates inter-limb
coordination. Animals therefore do not need to undergo
any complex process of training. They are allowed to
simply run freely along the glass walkway four to six
times. Data from the study show that their abnormal gait ,
in terms of stride length, duty cycle, dual diagonal
support, three-point support, four-point support, and base
of support between limbs persisted up to three weeks
post-MPTP administration. The parameters of inter-limb
coordination, regularity index, and step pattern showed no
significant difference in MPTP-treated mice, compared to
those of control mice. The extent of MPTP-mediated
nigrostriatal lesion might not elicit any observable dis-
coordination of tetrapod [33]. The observation may also
be related to stronger postural adjustment in quadrupeds
than in bipeds.
TH profiling at time of MPTP insult
MPTP-mediated dopaminergic cell loss occurred pre-
dominantly in the SN, whereas DA neurons in the ventral
tegmental area were less affected [8,51].
The remarkable reproducible neuroplasticity of the
nigrostriatal dopaminergic neurons after MPTP injury
has been reported in mice [52]. The decrease in the
expression of TH protein was noted to correlate with
the loss of DA neurons in the SN due to acute MPTP
injury [9]. It is likely that the decline in striatal dopa-
mine content was due to the decrease in the expression
of TH protein as a consequence of MPTP lesion. The
rescue of TH protein is one of the determinants for
regaining striatal dopamine in surviving nigrostriatal
dopaminergic neurons [40-42]. Readouts of western
blotting in the study demonstrated that protein levels of
TH in the SN and striatum appeared to rebound two
weeks post-MPTP administration; however the expressions
were still significantly lower than those derived from intact
SN and striatum.
The study data were in line with those reported previ-
ously by Ookubo et al. [53]. The TH protein level fell to
the lowest extent after three weeks. The stable lesion in PD
mice can serve as a proxy for Parkinsonism in mice, but
not for the assessment of MPTP neurotoxicity. The up-
regulated expression of TH protein expression two weeks
after MPTP injury might have a robust compensatory
increase resulted by surviving nigrostriatal dopaminergic
neurons against the neurotoxicity of the MPTP [54,55].
The study data suggest that the open field test is insensitive
to the extent of DA lesion except on day 4 and three weeks
post-MPTP challenge.
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treated mice
The study provided a thorough analysis of the very fine
locomotor aspects in a mouse model of sub-acute PD
mediated by MPTP. The CatWalk test revealed detailed
gait changes in mice at one week and three weeks post-
MPTP challenge. That stride length decreased markedly
in MPTP-treated mice may be the result of an increase
in muscle rigidity and hypokinesia [40,56,57]. Results of
the study were in accordance with previous studies
[23,27,34,58] and reports on PD patients [59-61], suggesting
that stride length serves as a successful translational
parameter for PD.
Bradykinesia is one of the major hallmarks of PD
[59,62]. Run duration, speed variation, swing speed, and
step cycle are parameters related to velocity in mobility
analysis. Using the CatWalk analysis system, we identified
a significant increase in walking duration accompanied
with a great variation in the walking speed in MPTP-
treated mice. The greater variation in walking speed,
which is similar to the fractal-like gait in PD, suggests
possible marked inconsistencies in the timing of gait and
inadequate postural adjustments [63-65]. The step cycle
was increased in the MPTP-treated mice of the study due
mainly to the longer contact between the paws and the
glass plate. Results of the study were in line with a previ-
ous gait assessment in a bilateral 6-OHDA rat model [34].
Gait cadence decreased significantly in MPTP-treated
mice. However, an increase in step frequency was noted in
PD [66,67]. Cadence varies directly with stride length and
inversely with the step cycle. The decrease in stride length
noted in MPTP-treated mice of the study might not
counter-balance the increase in the step cycle. As a conse-
quence, the cadence decreased in MPTP-treated mice.
Support, either temporal or spatial, is another aspect
related to gait in PD. The significant increases of initial
dual stance, terminal dual stance, three-point support,
and four-point support and the substantial decrease in
diagonal dual support in the study suggested an
increased duration of the postural phase in the MPTP-
treated mice. The study data agree with reports on a
longer double limb support time in PD, which may stem
from the long time taken to prepare for the generation
of propulsive forces [3,68]. Results are in line with delays
of freezing of gait or gait hesitation in PD [69-71]. The
increased duration of the postural phase and the
decrease in propulsive forces during the postural and
movement phases resulted in a shorter step length and a
slower step velocity. The spatial parameters of base of
support between hind limbs increased substantially in
MPTP-treated mice but there was no obvious difference
in base of support between fore limbs. This might be
related to hind limb rather than fore limb compensation,
at least in part, playing a role in the gait instability ofMPTP-treated mice in the study. On the other hand, the
study data contrast with the findings of Westin et al. in
which the base of support between fore limbs decreased
significantly after 6-OHDA injury. This might be attributed
to the difference in injured cerebral areas of animals in the
two studies [34].
Interlimb coordination parameters of regularity index
and step pattern were also studied. There are three
categories in the step patterns: cruciate (Ca, Cb), alternate
(Aa, Ab), and rotary (Ra, Rb). The ‘Ab’ alternate pattern is
the most common step cycle, constituting 80% to 95% of
the total step cycles in intact rodents, the other patterns
are very rare in intact animals. The Ab pattern remains
dominant in the Parkinson’s disease animal model [72]. In
this study, there was a slight but not significant decrease
in the incidence of this step pattern in mice after MPTP
injury. This result is supported by Chuang [33], and may
be related to stronger postural adjustment in quadrupeds
than in bipeds.
Correlation between the gait parameters and TH levels in
the SN
Various strategies have been employed to verify the cor-
relation between the motor deficits and the impairment
of the nigrostriatal system. Here, we used correlation
analysis of the motor parameters and TH protein levels
in the SN. Compared with the travel distance measured
in the open field test, parameters of the run duration,
stride length, duty cycle, swing speed, base of support
between hind limbs, three-point support, and four-point
support in the CatWalk test were much more strongly
correlated with the SN TH protein level. This is one of
the first studies to apply correlation analysis to gait mea-
sures and TH protein levels in the SN to further confirm
gait and posture deficits in the classic sub-acute MPTP
PD model.
Conclusion
This study reports novel and low-stress method of ana-
lyzing the motor functions of mice, which may be ap-
plied to monitor gait variability related to disease
progression and treatment strategy.
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